Table 4. Univariate and Multivariate Analysis of Factors Associated with Distant Metastasis-Free Survival.
| Variable | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age | 0.994 (0.940–1.050) | 0.822 | ||
| BMI | 1.000 (0.857–1.166) | 0.999 | ||
| Prostate volume measure by TRUS | 1.000 (0.971–1.029) | 0.991 | ||
| Risk classification | 0.005 | 0.073 | ||
| Low & intermediate | 1 (ref) | 1 (ref) | ||
| High | 3.458 (1.464–8.170) | 2.391 (0.922–6.203) | ||
| PSA | 0.395 | |||
| <20 | 1 (ref) | |||
| ≥20 | 0.421 (0.057–3.097) | |||
| Pathologic T stage | 0.867 | |||
| Organ confined (T2) | 1 (ref) | |||
| Non-organ confined (>T2) | 1.070 (0.483–2.370) | |||
| Pathologic Gleason score | 0.001 | 0.033 | ||
| <8 | 1 (ref) | 1 (ref) | ||
| ≥8 | 3.653 (1.737–7.686) | 2.463 (1.073–5.654) | ||
| Positive surgical margin | 0.556 (0.264–1.170) | 0.122 | ||
| PSA doubling time | 0.871 (0.779–0.975) | 0.016 | 0.875 (0.773–0.990) | 0.034 |
| Salvage radiotherapy | 0.324 (0.154–0.682) | 0.003 | 0.389 (0.183–0.826) | 0.014 |
| Early salvage ADT vs. delayed salvage ADT | 0.004 | 0.010 | ||
| Delayed salvage | 1(ref) | 1 (ref) | ||
| Early salvage | 0.205 (0.071–0.593) | 0.244 (0.084–0.714) | ||
ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; TRUS, transrectal ultrasonography.